Expanding the Scope of Precision Care for Patients With HR-Positive Breast Cancers

Join us live in Chicago or online for this 1.5-hour satellite symposium to hear experts discuss how they apply current clinical evidence to develop personalized treatment plans for HR-positive/HER2-negative early and advanced breast cancer, including the use of current and emerging oral targeted therapies and strategies to promote patient adherence. Bring your questions for the live Q&A session with the experts.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

Agenda

  • Welcome and Introduction
  • Assessing Risk and Individualizing Adjuvant Therapy in HR+/HER2- Early Breast Cancer
  • Selection and Sequencing of Targeted Therapy for HR+/HER2- Advanced and Metastatic Breast Cancer
  • Adverse Event Management and Strategies to Promote Adherence to Oral Targeted Therapies
  • Audience Question and Answer Session and Final Thoughts

Events

Date / Time
Event Details

Faculty

Program Chair
Komal Jhaveri, MD

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Assistant Professor of Medicine
Weill Cornell Medical College
New York, New York

Faculty
Erica Mayer, MD, MPH

Institute Physician
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Faculty
Laura M. Spring, MD

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to select and integrate new and emerging therapies into individualized treatment plans for HR+/HER2- breast cancer.

Target Audience
This program is intended for medical oncologists, pathologists, and other healthcare professionals who care for patients with breast cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan risk-adapted adjuvant treatment strategies for patients with early-stage HR+/HER2- breast cancer based on available evidence and use of risk assessment algorithms, cellular proliferation biomarkers, and multigene assays
  • Select individualized treatment for patients with HR+/HER2- metastatic breast cancer based on the available evidence, guidelines, tumor characteristics, patient preferences, and expert guidance
  • Apply appropriate strategies to increase medication adherence rates in breast cancer patients to improve outcomes and mitigate medication resistance

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.